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Radiofrequency ablation (RFA) of liver cancers can be performed safely using percutaneous, laparoscopic, or open surgical
techniques, and much of the impetus for the use of RFA has come from cohort series that have provided an evidence base for
this technique. Here, we give an overview of the current status of radiofrequency ablation (RFA) for hepatocellular carcinoma
(HCC), including its physical properties, to assess the characteristics that make this technique applicable in clinical practice. We
review the technical development of probe design and summarize current indications and outcomes of reported clinical use. An
accurate evaluation of treatment response is very important to secure successful RFA therapy since a suﬃcient safety margin (at
least0.5cm)canpreventlocaltumorrecurrences.Wealsoprovideaproﬁleofsideeﬀectsandinformationontheintegrationofthis
technique into the general management of patients with HCC. To minimize complications of RFA, physicians should be familiar
with each feature of complication. Appropriate management of complications is essential for successful RFA treatment. Moreover,
adjuvanttherapy,suchasmoleculartargetedtherapiesfollowingcurativetherapy,isexpectedtofurtherimprovesurvivalafterRFA.
1.Introduction
Hepatic resection forms part of the conventional treatment
for patients with hepatocellular carcinoma (HCC); however,
the majority of primary liver cancers are not suitable for
curative resection at the time of diagnosis. Diﬃculties of
surgical resection may be related to size, site, and number
of tumors, vascular and extrahepatic involvement as well
as liver function of the patient [1–4]. There is a need to
develop a simple and eﬀective technique for the treatment
of unresectable tumors within the liver. Therefore, local
ablative techniques (percutaneous ethanol injection (PEI),
microwave coagulation therapy (MCT), and radiofrequency
ablation (RFA)) have emerged in clinical practice to expand
the pool of patients considered for liver-directed therapies
[5–8]. Especially, RFA is not associated with some of the
side eﬀects of other ablative techniques [9]. Thus, RFA is
currently performed widely due to the ease of use, safety,
reasonable cost, and applicability to minimally invasive
techniques [10].
This paper reviews the evidence supporting the use of
RFA for HCC.
2.Background
2.1. Localized Application of Radiofrequency Energy. RFA
is a localized thermal treatment technique designed to
induce tumor destruction by heating the tumor tissue to
temperatures that exceed 60◦C[ 11]. The alternating current
of radiofrequency waves passing down from an uninsulated
electrode tip into the surrounding tissues generates changes
in the direction of ions and creates ionic agitation and fric-
tional heating. This tissue heating then drives extracellular
and intracellular water out of the tissue, resulting in tissue
destruction by coagulative necrosis [12, 13]. When tumor
cells are heated above 45–50◦C, intracellular proteins are
denatured and cell membranes are destroyed through disso-
lution and melting of lipid bilayers. As a result, successful
ablations usually increase the temperature of the ablated
tissue to above 60◦C.2 International Journal of Hepatology
Percutaneous RFA under local anesthesia was feasible,
although intraoperative RFA under general anesthesia was
also performed to prevent severe pain and discomfort during
the procedure.
2.2. RFA Electrodes and Generators. Three types of RF
electrodes are currently available commercially: two brands
ofretractableneedleelectrodes(model70andmodel90Star-
burst XL needles, RITA Medical Systems, Mountain View,
CA; LeVeen needle electrode, Boston Scientiﬁc, Boston, MA)
and an internally cooled electrode (Cool-Tip RF electrode;
Radionics, Burlington, MA) [14].
The needle electrodes of RITA consist of a 14-gauge
insulated outer needle that houses nine retractable curved
electrodes of various lengths. When the electrodes are
extended, the device assumes the approximate conﬁguration
of a Christmas tree. Nine of the electrodes are hollow and
contain thermocouples in their tips in order to measure
the temperature of adjacent tissue. The alternating electric
current generator comes in a 250 W model at 460kHz
(Model 1500X RF Generator, RITA Medical Systems). The
ablation algorithm is based on the temperature at the tips of
the electrodes. After the ablation cycle is completed, a tem-
perature reading from the extended electrodes in excess of
50◦C at 1min is considered to indicate satisfactory ablation.
Another RFA device (LeVeen Needle Electrode; Radio-
therapeutics) has retractable curved electrodes and an insu-
lated 17-gauge outer needle that houses 10 solid retractable
curved electrodes that, when deployed, assume the conﬁg-
u r a t i o no fa nu m b r e l l a .T h ee l e c t r o d e sa r em a n u f a c t u r e d
in diﬀerent lengths (2 to 4.0cm umbrella diameter). The
alternating electric current generator is 200W operated at
480kHz(RF3000;BostonScientiﬁc).Theablationalgorithm
is based on tissue impedance, and ablation is considered
successful if the device impedes out.
The third RFA device (Cool-Tip radiofrequency elec-
trode; Radionics) has an insulated hollow 17-gauge needle
with an exposed needle tip of variable length (2 or 3cm).
The tip of the needle contains a thermocouple to record the
temperature of adjacent tissue. The shaft of the needle has
two internal channels that allow the needle to be perfused
with chilled water. In an attempt to further increase the
size of the ablation area, the manufacturer placed three
of the cooled needles in a parallel triangular cluster with
ac o m m o nh u b .T h eg e n e r a t o rh a sap e a kp o w e ro u t p u t
of 200W and is operated at 480kHz (CC-1; Radionics).
The ablation algorithm is based on tissue impedance, and
ablationisconsideredsuccessfulifthedeviceimpedesout.As
a result, successful ablations usually increase the temperature
of the ablated tissue to above 60◦C.
2.3. Treatment Algorithm in Japan and the West. RFA is
basically recommended for HCC nodules with a maximum
diameterof3cminpatientswithnotmorethanthreetumors
who are contraindicated for surgery, although the typical
treatment algorithms in Japan, North America, and Europe
are each slightly diﬀerent [35].
One of the major treatment algorithms in Japan is
the “consensus-based clinical practice manual for HCC”
[14, 36] edited by the Japan Society of Hepatology (JSH).
This consensus recommends (1) hepatectomy for a single
tumor regardless of tumor size, but local treatment may
be selected for a tumor 2cm or smaller in Child-Pugh B
patients; (2) hepatectomy or local treatment when there
are 2 or 3 tumors and the tumor size is within 3cm; (3)
liver transplantation for Child-Pugh C patients with 3 or
fewer tumors 3cm or smaller or a single tumor with a
tumor size within 5cm (Milan Criteria); (4) RFA combined
with transcatheter arterial chemoembolization (TACE) is
recommended for tumors more than 3cm in diameter. RFA
isalsorecommendedfor4ormorenoduleswhereapplicable.
In Europe and North America, the algorithm established
bytheAmericanAssociationoftheStudyoftheLiverDisease
(AASLD) [37] recommends local treatment for 3 or fewer
3cm or smaller early-stage HCCs and 2-cm or smaller
very-early-stage HCCs with complications, such as portal
hypertension.
2.4. Assessment of Technical Eﬀectiveness. The assessment of
thetherapeuticeﬀectofRFAisveryimportant. Thetechnical
eﬀectiveness of ablation is commonly assessed by ﬁndings on
contrast-enhanced CT or MRI. A tumor was considered to
havebeen successfullyablatedwhentherewereno longerany
enhanced regions within the entire tumor during the arterial
phase and at least a 0.5cm margin of apparently normal
hepatic tissue surrounding the tumor during the portal
phase [38–40]. Failure to establish a suﬃcient ablative safety
margin was shown to be an independently signiﬁcant risk
factor for local tumor progression on multivariate analysis
[41]. Part of the tumor was diagnosed as remaining viable
when images of the ablated area showed nodular peripheral
enhancement [42].
Basically, the local recurrence rate following a single RFA
treatment depends on how strictly the therapeutic eﬀect is
assessed. In cases of HCC in which local curative therapy was
achieved by securing a safety margin, the 4-year survival rate
was relatively high, at 66%–82% (results in Japan) [35, 43].
3. ClinicalOutcomes
3.1. Percutaneous Approach
3.1.1. Survival: Comparison with Those after Resection.
A randomized control trial (RCT) has shown that RFA
achieved survival rates similar to those achieved by resection
(Table 1)[ 15]. Chen et al. conducted RCT on 180 patients
with a solitary HCC ≤5cm indicated to receive either
percutaneous RFA or surgical resection [15]. This study
showedthatpercutaneousRFAachievedthesameoveralland
disease-free survival rates as surgical resection for patients
with small solitary HCC. The 1- and 4-year overall survival
rates after percutaneous RFA and surgery were 95.8%, 67.9%
and 93.3%, 64.0%, respectively. The corresponding disease-
free survival rates were 85.9%, 46.4% and 86.6%, 51.6%,
respectively. Recently, Huang et al. reported an RCT trial in
which the 1-, 3-, and 5-year overall survival rates for the
RFAgroupandtheRESgroupwere86.96%, 69.57%, 54.78%
and 98.26%, 92.17%, 75.65%, respectively. Overall survival
and recurrence-free survival were signiﬁcantly higher in theInternational Journal of Hepatology 3
Table 1: Survivals: RFA versus hepatic resection for HCC.
Author/Year Study type n
(RFA/resection)
Mean tumor size
(cm)
(RFA/resection)
Overall survival (%)
(RFA versus resection) P
Chen et al. [15], 2006 RCT 90/90 ND/ND 65.9 versus 64.0 (4-year) NS
Huang et al. [16], 2010 RCT 115/115 ND/ND 54.78 versus 75.65 (5-year) .001
Vivarelli et al. [17],
2004 Retrospective 79/79 ND/ND 33 versus 65 (3-year) .002
Montorsi et al. [18],
2005 Prospective 58/40 ND/ND 30 versus 53 (4-year) .018
Ogihara et al. [19],
2005 Retrospective 40/47 4.6/7.4 39 versus 31 (5-year) .79
Wakai et al. [20], 2006 Retrospective 64/85 ND/ND 30 versus 53 (10-year) .012
Guglielmi et al. [21],
2008 Retrospective 23/33 ND/ND 45 versus 55 (5-year) .7
Abu-Hilal et al. [22],
2008 Retrospective 34/34 3.0/3.8 57 versus 56 (5-year) .3
Hiraoka et al. [23],
2008 Retrospective 105/59 ND/ND 59.3 versus 59.4 (5-year) NS
Ueno et al. [24], 2009 Retrospective 123/110 2.0/2.7 63 versus 80 (5-year) .06
Takayama et al. [25],
2009 Retrospective 1315/1235 1.6/1.8 95 versus 94 (2-year) .28
HCC: hepatocellular carcinoma; ND: not described; NS: not signiﬁcant; RFA: radiofrequency ablation.
Table 2: Local tumor progression rates after RFA for HCC.
Author Year n Tumor size
(mean, cm)
Follow-up period
(mean, months)
Local tumor
progression rate
(%)
Rossi et al. [26] 1996 41 2.3 22.6 5.0
Buscarimi et al. [27] 2001 60 ND 26.8 14
Choi et al. [28] 2004 53 2.1 23 21
Lu et al. [29] 2005 87 2.5 12.7 5.8
Shiina et al. [30] 2005 118 ND 34.8 1.7
Solmi et al. [31] 2006 63 2.8 32.3 41
H¨ ansler et al. [32] 2007 21 4.2 ND 21
Waki et al. [33] 2010 88 ND 36 4.8
Li et al. [34] 2010 117 2.4 21 9.4
HCC: hepatocellular carcinoma; ND: not described; RFA: radiofrequency ablation.
surgical resection group than in the RFA group (P = .001,
P = .017). However, percutaneous RFA can be expected
to have an advantage over liver resection in providing a
better short-term postoperative result because local ablative
therapy is a less invasive procedure [16–25].
3.1.2. Local Controllability (Local Tumor Progression). The
local recurrence rate after RFA for HCC ranged from 1.7%
to 41% [26–34]( Table 2). Local tumor progression is related
to incomplete tumor ablation. It is often diﬃcult to obtain a
speciﬁc safety margin in three dimensions all around a large
tumor. Some researchers reported that the most important
factor associated with failure of local tumor control could be
tumor size [8, 36–38]. In Table 2, local tumor progression
did not necessarily depend on the tumor size; however,
recurrence could occur even after a suﬃcient margin had
been ensured. It is considered that local recurrence appears
toarisefromresidualcancerafterRFAwhilerecurrencefrom
a microsatellite or by microvascular invasion other than the
main nodule may also appear as a late local recurrence. The
local tumor progression rate can diﬀer markedly depending
on whether or not a 5mm circumferential safety margin
has been secured. Nishijima et al. categorized the presence
of no margin, a partially lacking margin, margin narrower
than 5mm, and complete margin wider than 5mm as R0,
R1, R2, and R3 on the assessment of the therapeutic eﬀect
of RFA, respectively, and found signiﬁcant diﬀerences in the
localrecurrenceratebetween R0andR1andbetween R2and
R3. The local recurrence rate signiﬁcantly diﬀered between
patients with and without a suﬃcient safety margin [44].4 International Journal of Hepatology
Therefore, ensuring a safety margin in RFA is important
for not only the simultaneous treatment of microsatellite
lesions, but also to ensure suﬃcient tumor ablation on the
assumption of a partial volume eﬀect-associated limitation
on evaluation of the therapeutic eﬀect by imaging.
3.1.3. Advances of Techniques: Large HCC. T u m o rs i z ei sa n
important factor inﬂuencing the local recurrence rate after
RFA[45].ToincreasethesizeofthecoagulationzoneinRFA,
physicians have tried using vascular occlusion during RFA
because vascular occlusion reduces heat dispersion. It was
shown in the consensus meeting “HCC Treatment” at the
45th Annual Meeting of the JSH in Kobe in 2009 [46] that
about 90% of physicians performing RFA employ lipiodol
TACE-preceded RFA for 3cm or larger HCCs. Lipiodol
TACE-preceded RFA is relatively curative and can be readily
performedforthefollowingreasons:(1)lipiodolregurgitates
into the portal branches via the peribiliary venous plexus,
causing a transient state of liver infarction, which reduces the
cooling eﬀect, expanding the ablative area, and resulting in
(2) coagulation of satellite lesions [43]. Peng et al. reported a
series of 120 patients with HCC, and the 1-, 3-, 5-year overall
survival rates for TACE-preceded RFA and RFA groups were
93%,75%,50%,and89%,64%,42%,respectively(P = .045)
[47]. Yamakado et al. reported that the survival rates of
large HCC cases treated with resection and lipiodol TACE-
preceded RFA were almost equivalent [48]. TACE combined
with RFA therapy might improve the overall survival status
for patients with large HCCs (Table 3)[ 47, 49–52].
3.1.4. Advanced Techniques: Tumors Abutting the Diaphragm
and Gastrointestinal Tract. Ultrasound- (US-) guided pro-
cedures are necessary but limited for tumors located under
the diaphragm. However, saline solution injection into the
pleural cavity can separate the lung and liver on B-mode US,
that is, artiﬁcial pleural eﬀusion acts as an acoustic window.
There are reports on the feasibility and safety of RFA with
artiﬁcially induced pleural eﬀusion for HCC located in the
right subphrenic region [53–56]. In a series of 24 patients
with HCC located in the hepatic dome, 200–1100mL of 5%
glucose solution was infused intrathoracically to separate the
lung and liver, thus, complete tumor necrosis in a single
session was achieved in 96.4% [56].
Artiﬁcialpreparationofaspacebetweentheintestineand
nodule by infusing normal saline or 5% glucose (artiﬁcial
ascites method) for treatment has recently become possible
[57,58].Thesetechniquesmarkedlyexpandedtheindication
for RFA. Laparoscopic resection or laparotomic RFA had
to be inevitably performed in patients with HCC nodules
<2.0cm in diameter before the introduction of artiﬁcial
ascites, but more than 90% of cases are now treatable by the
“artiﬁcial ascites method”.
3.1.5. Advanced Techniques: Cases That Are Unclear on B-
Mode US. Multiple RFA sessions for HCCs were frequently
required because of HCC nodules that are unclear on B-
mode US. Under CT ﬂuoroscopy using either CT arteriog-
raphy or iodized oil injection, we can target and puncture
hepatic malignancies using a percutaneous ethanol injection
needle. Real-time CT ﬂuoroscopy is useful to guide the
needle puncture and to monitor ethanol injection in small
hepatic malignancies [67]. Another merit is that the eﬃcacy
of treatment can be evaluated using contrast enhanced CT
immediately after treatment.
Contrast enhanced harmonic US imaging is able to
evaluate small hypervascular HCCs even when B-mode US
cannot adequately characterize the tumors [68–72]. The
microbubbles of these contrast agents provide stable nonlin-
ear oscillation in a low-power acoustic ﬁeld because of the
hardshellsofthesebubbles,producinggreatdetailinthehar-
monic signals in real time [71–73]. It has been reported that
contrast harmonic sonography-guided RFA is an eﬃcient
approach for guiding further ablation of hepatic malignan-
cies that are not clearly demarcated by B-mode US [74–78].
Virtual CT sonography using magnetic navigation (Real-
time Virtual Sonography (RVS); HITACHI Medico, Tokyo,
Japan) provides cross sectional images of CT volume data
corresponding to the angle of the transducer in the magnetic
ﬁeld in real-time. This imaging technique displays a real-
time synchronized multiplanar CT image in precisely the
same slice of the US plane. Thus, RVS can be used for
real-time needle insertion guidance, especially for nodules
demonstrated on CT, but not on US [79, 80].
3.2. Laparoscopic/Open Surgical Approach. The use of a
laparoscopic or open approach allows repeated placement of
RFA electrodes at multiple sites to ablate larger tumors [59–
66]( Table 4). Moreover, a hand-assisted technique can be
appliedsafelyandeﬀectivelytolaparoscopicliversurgeryand
oﬀers the advantages of intraoperative US, which provides
better resolution of the number and location of liver tumors.
The postoperative recovery of patients was shorter compared
with that after an open surgical approach. Ishiko et al.
reported that the surgical procedures consisted of 5 RFA
sessions for tumors in the caudate lobe with hand-assisted
laparoscopic surgery (HALS) and a postoperative CT scan
demonstrated suﬃcient ablation in all patients and there was
no surgical mortality [63]. The HALS approach has several
advantages;itfacilitatesandexpeditestheprocedure,reduces
the stress factor on the surgeon, greatly improves exposure,
and facilitates immediate and eﬃcient control of bleeding
vessels with the internal hand. However, the local treatment
failure rate of the laparoscopic approach was higher in
patientswithHCCnodulessituateddeepwithintheliverand
measuring 4 cm or more in diameter [81]. Great diﬃculty
can be encountered during treatment of lesions in contact
with the diaphragm.
Although more invasive, open RFA can be performed
more easily, and the puncture course of RF needle can
be more widely selected than that during laparoscopic
approach. Some have reported that patients undergoing
radical open RFA demonstrated few ablation site recurrences
even though the nodules measured more than 4 cm in diam-
eter and/or there were more than three nodules [59, 62, 65].
3.3. Complications. A recent review indicated that compli-
cation rates for percutaneous, laparoscopic, and open RFA
of hepatic tumors in 3670 patients were 7.2%, 9.5%, andInternational Journal of Hepatology 5
Table 3: Survivals: RFA combined with TACE versus RFA alone for HCC.
Author/year n
(TACE+RFA/RFA)
Tumor size (mean, cm)
(TACE+RFA/RFA)
Overall survival (%)
(TACE+RFA/RFA) P
Kitamoto et al. [49]/2003 10/16 3.9/3.4 ND
Wang et al. [50]/2007 43/40 ND 68.3/57.6 (1-year) <.05
Shibata et al. [51]/2009 46/43 ND 84.8/84.5 (3-year) .515
Morimoto et al. [52]/2010 19/18 3.6/3.7 93/80 (3-year) .369
Peng et al. [47]/2010 120/120 ND 50/42 (5-year) .045
HCC: hepatocellular carcinoma; ND: not described; RFA: radiofrequency ablation, TACE: trans catheter arterial chemoembolization.
Table 4: Laparoscopic/open RFA for liver malignancies: local tumor progressions and survivals.
Author/year Arms n Tumor size
(mean, cm)
Follow-up period
(mean, months)
Local tumor
progression
Survival
(%)
Topal et al. [59]/2003 LS/open 9/9 3.8/3.5 12.2 1/9, 0/9 ND
Berber et al. [60]/2005 LS 66 4.1 25.3 ND 38% (3-year)
Hildebrand et al. [61]/2007 LS 14 ND 23.2 1/14 ND
Minami et al. [62]/2007 open 30 3.2 18.9 1/30 71.6%
(3-year)
Ishiko et al. [63]/2008 HALS 5 ND 32.2 1/5 ND
Ballem et al. [64]/2008 LS 104 3.5 23 ND 21% (3-year)
Tanaka et al. [65]/2009 open 26 ND ND 1/26 ND
Salama et al. [66]/2010 LS 72 ND 14.3 2/72 ND
HALS: hand-assisted laparoscopic surgery; LS: laparoscopy; ND: not described; RFA: radiofrequency ablation.
9.9%, respectively [82]. Overall, the frequency of major
complications of percutaneous RFA ranged from 0.6%–
8.9%, which was higher than that of PEI, but generally less
than that of MCT [43]. Complications of percutaneous RFA
reported in 2320 patients treated at 41 diﬀerent hospitals in
Italy indicate that the mortality rate was 0.3% with an overall
complication rate of 7.1% [83, 84]. The authors described
major complications (2.4% incidence) including death,
hemorrhage, RFA needle-track seeding, RFA lesion abscess,
perforation of gastrointestinal viscus, liver failure, biloma,
biliary stricture, portal vein thrombosis, and hemothorax or
pneumothorax requiring drainage, and minor complications
(4.7% incidence) including pain, fever, and asymptomatic
pleural eﬀusion. Although Llovet et al. [85] reported that
dissemination along puncture route was observed in 12.5%
of their patients, dissemination might not occur at such
a high frequency. This complication was almost absent in
many reports from Japan [43].
Theoretically, a tumor that is contiguous to a large vessel
is more likely to have some viable tumor cells following
local thermal therapy because there is a signiﬁcant tissue
cooling eﬀect caused by blood circulation of normal body
temperature. Thus, the eﬀort to thoroughly ablate the lesion
with a safety margin under such conditions increases the
total number of electrode insertions, and this may increase
the risk of complications. Some investigators have suggested
that tumor location is closely related to the risk of major
complications. Central tumors close to the hepatic hilum
werereportedtobeunsuitableforpercutaneousRFAbecause
of the risk of injuring adjacent bile ducts [7]. Moreover,
peripheral tumors adjacent to extrahepatic organs were also
suggestedtobeunsuitablebecauseoftheriskofheatinjuries,
such as intestinal perforation and pleural eﬀusion [84, 86].
However, Teratani et al. reported that there was no diﬀerence
in early complication rates according to tumor location [87].
The eﬀort to achieve thorough ablation increased the total
number of electrode insertions, and this may have led to an
increase in complications.
Not only elevating the survival rate and reducing the
incidenceoflocalrecurrencebutalsoavoidingcomplications
as much as possible are major tasks. To minimize compli-
cations of RFA, knowledge of risk factors and prevention
methods is required. In addition, because early and accurate
diagnosis is necessary for the appropriate management of
complications, physicians should be familiar with all features
of complication.
4.FuturePerspective
Currently, a multicenter randomized controlled study (pro-
spective randomized study of surgery or RFA for early HCC:
SURF Trial) is underway in Japan, involving patients with 3
or fewer tumors 3 cm or smaller for which both hepatectomy
and RFA are applicable [88], and a large global study is
currently underway (the Sorafenib as Adjuvant Treatment
in the Prevention of Recurrence of HepatocellularCarcinoma6 International Journal of Hepatology
(STORM) trial), looking at the eﬃcacy of sorafenib therapy
after potentially curative treatment with liver resection or
RFA.
5. Conclusion
Here, we have assessed the role of RFA in the overall
therapeutic strategy for patients with HCC and highlighted
deﬁciencies in current knowledge. We intend to strive for a
balanced discussion between the tendency to overemphasize
the potential advantages of RFA and the tendency to
understate a potentially useful treatment. Percutaneous RFA
can achieve the same overall and disease-free survival rates as
surgical resection for patients with small HCC, while causing
few side eﬀects. Percutaneous RFA combined with TACE will
make the treatment of larger tumors a clinically viable treat-
ment alternative. The use of a laparoscopic or open approach
allows repeated placement of RFA electrodes at multiple sites
to ablate larger tumors. In addition, an accurate evaluation
of treatment response is very important to secure successful
RFA therapy since a suﬃcient safety margin (at least 0.5cm)
can prevent local tumor recurrence. Adjuvant therapy, such
as molecular targeted therapies following curative therapy, is
expected to further improve survival after RFA.
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